3/29/2022

speaker
Crystal
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Infinity Pharmaceuticals conference call to discuss the company's operations and full year 2021 financial results. My name is Crystal, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this conference is being recorded at Infinity's request. Now, I would like to introduce your host for today's call, Jane Kaufman. Please go ahead.

speaker
Jane Kaufman
Host

Thank you, Crystal, and good afternoon, everyone. Welcome to today's call to discuss our recent business progress and review of our full year 2021 financial results and company highlights. On the call with me today are Adeline Perkins, Chief Executive Officer and Chair, Larry Block, President, and Robert Alaria, Jr., Chief Medical Officer. We'll open the call for Q&A following our remarks. The press release issued today details our results and is available on our website at INFE.com. Please note that during this call, we may make forward-looking statements about our future expectations and plans, including clinical development objectives, the therapeutic potential of our product candidates, our strategic plans and strategies, and financial projections. Our actual results may differ materially from what we project today. due to a number of important factors, including the considerations described in the risk factor section of our annual report on Form 10-K for 2021 and in other filings we make with the SEC. These forward-looking statements represent our views only as of today, and we caution you that we may not update them in the future, whether as a result of new information, future events, or otherwise. Now, I'd like to turn the call over to Adeline.

speaker
Adeline Perkins
Chief Executive Officer and Chair

Thanks, Jane. And thank you to everyone for joining us today to review Infinity's key 2021 accomplishments and 2022 goals. Even against the challenging backdrop of a global pandemic, geopolitical tensions, and deteriorating capital markets, Infinity was able to make meaningful progress during 2021 and is well positioned to weather future storms. The four foundational pillars necessary to create great value are all in place. with a differentiated drug, good clinical data, an augmented leadership team, and a strengthened balance sheet. Building on these in 2022, we are now poised to initiate the first aganalysib registration study, expand aganalysib clinical evaluation in multiple additional solid tumor indications, and establish the best path forward to continue to fund and maximize the value of aganalysib for patients and shareholders. Before turning to 2022, I'll review the four foundational pillars which are enabling us to optimize the value of aganalysib, our first-in-class drug that reprograms macrophages in the tumor microenvironment to reduce immune suppression and activate an immune attack against cancer. The power of this unique mechanism has been underscored by robust clinical and translational data presented over the last 18 months. We disclosed positive results in five solid tumors across CITC 2020, San Antonio Breast Cancer Symposium in 2020 and 2021, as well as ASCO-GU 2021. These presentations included data in three different combination regimens and multiple lines of therapy and tumor types, including metastatic triple negative breast cancer, or TNBC, metastatic urothelial cancer, or UC, ovarian cancer, as well as checkpoint inhibitor resistant squamous cell cancer of the head and neck, and melanoma. All settings where checkpoint inhibitors have provided more limited patient benefit to date. These data validate aganalysis potential to increase the effectiveness of current standards of care including in the PD-L1 negative patient populations for whom checkpoint inhibitors alone are particularly ineffective. The encouraging results across five distinct tumor types are impressive in their own right, and yet the totality of the data are even more compelling in light of the consistent patient benefit seen across multiple settings. Improvements in both median progression-free survival and median overall survival further underscore the promise of aganalysib to drive the next generation of immuno-oncology combination therapy. On today's call, we'll focus specifically on the data from two of these studies, in patients with frontline metastatic TNBC from our MARIO3 study and in patients with second-line metastatic UC from our MARIO275 study. In addition to having a first-in-class drug with good data, The broad potential began to listen, has enabled us to strengthen another foundational pillar, our team. In 2021, we expanded our clinical and scientific leadership and are already benefiting from the experience and momentum being driven by our chief medical officer, Dr. Robert Alaria Jr., our chief scientific officer, Dr. Stefan Peluso, and our former chief medical officer and now board member, Dr. Brian Schwartz. In addition, Today I am very pleased to announce the addition of Sujay Kengo to our Board of Directors. Sujay was most recently the Chief Commercial Officer at Acceleron, prior to its acquisition by Merck late last year, and previously served as Infinity's Executive Vice President and Chief Commercial Officer. Sujay will be providing important commercial and strategic insights as a member of our Board, which is very timely as we initiate our first registration study for a GANalyst of this year. And last but not least, in 2021, we strengthened our balance sheet, having raised $92 million in the first quarter of last year. With over $80 million on our balance sheet at the beginning of 2022, we have the resources required to initiate our registration trial in frontline metastatic TMDC and expand our development of Eganilisa through our MarioP study this year. Altogether, we are very encouraged that even in the face of global uncertainty and market volatility, Infinity's future is bright. I'll now turn the call over to Rob to review the data that supports this bright future for the studies we are initiating this year, as well as potential future development paths.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-